Patents by Inventor Sirkka RM Kyostio-Moore

Sirkka RM Kyostio-Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT CONDITIONS IN MAMMALS
    Publication number: 20200231940
    Abstract: The present disclosure relates to recombinant viral vectors, to pharmaceutical compositions comprising such recombinant vectors, and to methods for prevention and treatment of osteoarthritis in mammals. In particular, this disclosure provides adeno-associated virus (AAV) vectors capable of expressing, in a host, osteoprotective/chondroprotective bioactive proteins, including hyaluronan synthase 2 (HAS2) and lubricin (PRG4). Methods of production of these AAV are provided, as are methods of treatment of osteoarthritis in mammalian joints, by the long-term gene expression of osteoprotective/chondroprotective proteins, including HAS2 and PRG4, in both synovial and chondrocyte cells.
    Type: Application
    Filed: July 29, 2019
    Publication date: July 23, 2020
    Inventors: Monica DIAS FIGUEIREDO, Sirkka RM KYOSTIO-MOORE, Patricia BERTHELETTE
  • Recombinant AAV Vectors Expressing Osteoprotective genes, including HAS2 and Lubricin, useful in the Treatment of Osteoarthritis and Related Joint Conditions in Mammals
    Publication number: 20170198263
    Abstract: The present disclosure relates to recombinant viral vectors, to pharmaceutical compositions comprising such recombinant vectors, and to methods for prevention and treatment of osteoarthritis in mammals. In particular, this disclosure provides adeno-associated virus (AAV) vectors capable of expressing, in a host, osteoprotective/chondroprotective bioactive proteins, including hyaluronan synthase 2 (HAS2) and lubricin (PRG4). Methods of production of these AAV are provided, as are methods of treatment of osteoarthritis in mammalian joints, by the long-term gene expression of osteoprotective/chondroprotective proteins, including HAS2 and PRG4, in both synovial and chondrocyte cells.
    Type: Application
    Filed: January 13, 2017
    Publication date: July 13, 2017
    Applicants: MERIAL INC., GENZYME CORPORATION
    Inventors: Monica Dias Figueiredo, Sirkka RM Kyostio-Moore, Patricia Berthelette